JPS62181219A - Remedy for decubitus - Google Patents
Remedy for decubitusInfo
- Publication number
- JPS62181219A JPS62181219A JP2247086A JP2247086A JPS62181219A JP S62181219 A JPS62181219 A JP S62181219A JP 2247086 A JP2247086 A JP 2247086A JP 2247086 A JP2247086 A JP 2247086A JP S62181219 A JPS62181219 A JP S62181219A
- Authority
- JP
- Japan
- Prior art keywords
- water
- acid
- composition
- carbonate
- organic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011985 Decubitus ulcer Diseases 0.000 title claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 150000007524 organic acids Chemical class 0.000 claims abstract description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 10
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract description 22
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract description 11
- 239000001569 carbon dioxide Substances 0.000 abstract description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 4
- 239000001384 succinic acid Substances 0.000 abstract description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract description 2
- 235000015165 citric acid Nutrition 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000001530 fumaric acid Substances 0.000 abstract description 2
- 235000011087 fumaric acid Nutrition 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000001630 malic acid Substances 0.000 abstract description 2
- 235000011090 malic acid Nutrition 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 235000002906 tartaric acid Nutrition 0.000 abstract description 2
- 239000011975 tartaric acid Substances 0.000 abstract description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract description 2
- -1 NaHCO3 Chemical compound 0.000 abstract 2
- 239000003814 drug Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 229910000031 sodium sesquicarbonate Inorganic materials 0.000 description 1
- 235000018341 sodium sesquicarbonate Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は褥迩治僚剤、更に詳細には外用の褥唐治僚剤に
関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a bed-adjusting agent, and more particularly to a bed-adjusting agent for external use.
褥癒は、一般には一定の部位を長い間圧迫することによ
り、循環障害がおこり発生するものである。しかしなが
ら、脳梗塞、糖尿病などの場合には、短期間で発生する
こともあシ、様々な要因が関与すると考えられている。Bed sores generally occur when pressure is applied to a certain area for a long period of time, resulting in circulatory disorders. However, in cases of cerebral infarction, diabetes, etc., it is thought that they may occur in a short period of time and that various factors are involved.
而して、褥槍は、臀部、坐骨部など骨の飛び出している
所に発生しやすく、進むと潰瘍になる。潰瘍は皮膚の表
面よシも皮膚の深部にできて皮膚が破れ、更に大きな潰
瘍となることもある。Therefore, bedsores tend to occur in areas where bones protrude, such as the buttocks and ischial area, and if they progress, they will develop into ulcers. Ulcers can form on the surface of the skin or deep within the skin, causing the skin to break and develop into larger ulcers.
一度褥逅が出来ると治癒はかなり困難であり、その治療
方法としては、局所の消毒、抗生剤の役。Once a pressure ulcer occurs, it is very difficult to heal, and the treatment methods include local disinfection and the use of antibiotics.
与、インシュリン塗布、ホルマリン処置のガーゼ使用、
渦流浴の実施など多くの方法が試みられている。administration, insulin application, use of gauze for formalin treatment,
Many methods have been tried, including the implementation of whirlpool baths.
しかしながら、特に体力的に低下している患者（主に老
人）の場合には症状の改善が翔しく、良い治療方法が未
だ確立していないのが実状である。However, the improvement in symptoms is rapid especially in the case of physically weakened patients (mainly elderly people), and the reality is that good treatment methods have not yet been established.
本発明者らは、かかる実状に鑑み鋭意研究を行なった結
果、炭酸塩と有機酸を含有する組成物を水に溶解せしめ
ることにより得られる二酸化炭素を一定濃度以上含有す
る溶液を褥唐部位に適用することにより、褥艙が著しく
改善されることを見出し、本発明を完成した。The present inventors conducted extensive research in view of the above circumstances, and as a result, the present inventors applied a solution containing a certain concentration or more of carbon dioxide, which is obtained by dissolving a composition containing carbonate and an organic acid in water, to the bedside area. It was discovered that by applying this method, bed beds were significantly improved, and the present invention was completed.
すなわち本発明は、炭酸塩と有機酸を首有し、その０．
１重量ｑ６水溶液のｐＨが４〜７であり、水中で反応し
てガス泡を発生する組成物（以下、４癒治療剤用組成物
という）を水に溶解せしめることにより得られる、二酸
化炭素を３００ ｐｐｍ以上官有する溶液からなる褥唐
治療剤を提供するものである。That is, the present invention has a carbonate and an organic acid, and 0.
Carbon dioxide, which is obtained by dissolving in water a composition that reacts in water and generates gas bubbles (hereinafter referred to as the composition for 4 healing agents), whose pH of 1 weight q6 aqueous solution is 4 to 7. The present invention provides a bed rash treatment comprising a solution containing 300 ppm or more.
本発明に係る褥債治僚剤用組成物に使用さする炭酸塩と
しては、例えば炭酸水素す） ＩＪウム、炭酸ナトリウ
ム、セスキ炭酸ナトリウム、炭酸水素カリウム等が挙げ
られる。これらは単独で又は２橿以上を組み合せて使用
することができる。Examples of carbonates used in the composition for pressure relief agent according to the present invention include hydrogen carbonate, sodium carbonate, sodium sesquicarbonate, potassium hydrogen carbonate, and the like. These can be used alone or in combination of two or more.
また、有機酸としては、例えばコハク酸、フマル酸、ク
エン酸、酒石酸、リンゴ酸等が挙げられ、これらは単独
で又は２８１以上を組合わせて使用することができる。Further, examples of organic acids include succinic acid, fumaric acid, citric acid, tartaric acid, malic acid, etc., and these can be used alone or in combination of 281 or more.
炭酸塩と有機酸の配合量は、褥癒治僚剤用組成物の０．
１″ＩＬ１：ｔｓ水溶液の−が４〜７になるようにする
ことが必要である。該水溶液の−がアルカリ側では、二
酸化炭素は溶液中に炭酸イオン、重炭酸イオンとして存
在するため、褥癒の改畳効果は認められないが、酸性側
では、二酸化炭素分子として存在するため、４艙の改善
効果を奏するものと考えられる。また、−が４より低い
と傷等に刺激を与えることがあり好ましくない。The blending amounts of carbonate and organic acid are 0.
1"IL1:ts It is necessary to adjust the aqueous solution so that the - value is 4 to 7. If the - value of the aqueous solution is on the alkaline side, carbon dioxide exists in the solution as carbonate ions and bicarbonate ions. Although no healing effect is observed, on the acidic side, it exists as carbon dioxide molecules, so it is thought to have an improvement effect of 4.Also, if - is lower than 4, it may irritate wounds, etc. This is not desirable.
かかる粂件を具備するための有機酸の配合ｔは、有機酸
の種類によって異なる。例えばコハク酸の場合は、コハ
ク酸の配合量を炭酸塩（炭酸水素ナトリウムに換算して
）の２０〜２００重量Ｓとなるようにするのが好ましい
。The blend of organic acids to provide such properties differs depending on the type of organic acid. For example, in the case of succinic acid, the amount of succinic acid blended is preferably 20 to 200 S by weight of carbonate (in terms of sodium hydrogen carbonate).
４艙治療剤用組成物には、上記炭酸塩及び有機酸の必須
成分の他に、消炎剤、殺菌剤、抗生物質、創傷治癒促進
剤、ビタミン類等の任意成分を配合することができる。In addition to the above-mentioned essential components of carbonate and organic acid, optional components such as anti-inflammatory agents, bactericidal agents, antibiotics, wound healing promoters, vitamins, etc. can be added to the composition for therapeutic agents.
なお、これら任意成分は、必要に応じて、褥艙治僚削に
別途添加することもできる。Incidentally, these optional components can also be separately added to the bedspread dressing, if necessary.
また、その剤型は粉末、顆粒、錠剤等の形にすることが
でき、これらの製剤化のために、必要に応じて賦形剤、
結合剤、崩壊剤、滑沢剤等を添加することができる。In addition, the dosage form can be in the form of powder, granules, tablets, etc. To prepare these formulations, excipients,
Binders, disintegrants, lubricants, etc. can be added.
本発明の４逅治療剤は、４連治療剤用組成物を、その水
溶液中の二酸化炭素の濃度が３００ ｐｐｍ以上、好ま
しくは５００ ｐｐｍ以上となるように水、好ましくは
温水に溶解せしめることによシ調表される。二酸化炭素
をかかる６度含有する溶液は、例えば褥艙治僚剤用組成
物５〜２５０１を５〜２０１の水又は温水Ｖζ溶解する
ことにょシ得ることができる。The quadruple therapeutic agent of the present invention is obtained by dissolving the composition for the quadruple therapeutic agent in water, preferably warm water, such that the concentration of carbon dioxide in the aqueous solution is 300 ppm or more, preferably 500 ppm or more. It is expressed well. Such a solution containing 6 degrees of carbon dioxide can be obtained, for example, by dissolving Composition 5-2501 of bedspread medicine in 5-201 of water or warm water Vζ.
本発明の４厘治療剤の使用方法としては、例えば１日数
回該治療剤に１回あた＃）１０〜３０分間患部を浸漬す
る方法、該治療剤をガーゼやタオル等に含ませたものを
患部にあて、好ましくはガーゼ又はタオル等のＦから湯
枕等によって温める方法等が挙げられる。かかる処置を
数日〜数ケ月続けることにより著しい症状の改善がみら
れる。Methods for using the 4-pot therapeutic agent of the present invention include, for example, soaking the affected area in the therapeutic agent several times a day for 10 to 30 minutes, or soaking the therapeutic agent in gauze, towels, etc. Examples include a method of applying the liquid to the affected area and warming it, preferably with a cloth such as gauze or a towel, and a hot water pillow. By continuing such treatment for several days to several months, significant improvement in symptoms can be seen.
本発明褥府治療剤の褥徐に対する作用としては、二酸化
炭素の血流促進作用あるいは二酸化炭素と炭酸塩、有機
酸ンこよる相乗ｒμ用が考えられるが、その詳細は不明
である。The effect of the treatment agent for bedsores of the present invention on bedsores is thought to be the blood flow promoting action of carbon dioxide or the synergistic rμ effect of carbon dioxide, carbonates, and organic acids, but the details are unknown.
本発明褥債治療剤は、後記実施例に示す如く、原因の如
何を問わず、難治性の褥癒に対して著しい改善効果ｔ−
奏する。As shown in the Examples below, the therapeutic agent for bedsores of the present invention has a remarkable improvement effect on refractory bedsores regardless of the cause.
play.
次に実施例を挙げて説明する。 Next, an example will be given and explained.
実施例１
４倫治療用組成物：
（組成）
炭酸ナトリウム １６（重量部）重炭酸ナトリ
ウム ３４
コハク酸 ４４
ポリエチレングリコール６０００ ６Ｅ記組成
物分成型して１錠５０．９の錠剤とした。Example 1 Composition for treatment of 4Run: (Composition) Sodium carbonate 16 (parts by weight) Sodium bicarbonate 34 Succinic acid 44 Polyethylene glycol 6000 The composition described in 6E was molded into tablets with a weight of 50.9 kg.
実施例２
７７オの女性。多発性脳梗塞と糖尿病、高皿圧症の基礎
疾患を有し、踵に血行不全による４艙が生じた。軟１ｆ
塗擦・消４処置による治療を数ケ月続けたが改善がみら
れないため、実施例１で得た錠剤１個を１０１の温水に
とかして下腿部を約２０分間定容（１日２回）させた。Example 2 A 77-year-old woman. He had underlying conditions such as multiple cerebral infarctions, diabetes, and high platelet pressure syndrome, and suffered from four heel cavities due to poor blood circulation. soft 1f
After several months of treatment with smearing and exfoliation, no improvement was seen, so one tablet obtained in Example 1 was dissolved in 101 warm water and applied to the lower leg for about 20 minutes (twice a day). ).
当初、４唐面積が１５．９ｉであったのが、３ケ月後に
は完治した。Initially, the area of 4 tang was 15.9i, but it completely recovered after three months.
実施例３ ８４才の男性。多発性脳梗塞、慢性気管支炎。Example 3 84 year old man. Multiple cerebral infarctions, chronic bronchitis.
左足踵に４債ができ、ヒビテン消毒、軟膏塗擦による治
療を約２ケ月行ったが改善がみられないため、実施例１
で得た錠剤１個を１０／の温水に溶かして下腿部を約２
０分間定容（１日２回）させた。当初、１．５ｃ！ＩＬ
の４皆が１ケ月後には完治した。Example 1: There was a 4-bond on the heel of the left foot, and treatment with Hibiten disinfection and application of ointment was performed for about 2 months, but no improvement was seen.
Dissolve 1 tablet obtained in 10 parts of warm water and apply about 2 parts to the lower leg.
0 minutes at a constant volume (twice a day). Initially, 1.5c! IL
All four patients made a full recovery after one month.
実施例４
７０オ男性。脳出血後、２４日日日より仙骨部に４癒が
発生したため局所消毒、軟責浴布による治療を１ケ月程
行っていたが、改善せず、むしろ拡大傾向にあつ九。そ
こで実施例１で得た錠剤１個を５ｊの温水に溶かし念溶
液に清潔なタオルを浸し、そのタオルｔ−４ｉ部にあて
、その旧にビニールシートを載せ、更にこのシートの上
から４２℃の温水の入った湯枕をあてて３０分間保温す
る処置を１日２回行った。当初、９Ｘ７儂の大きさの４
癒が、２ケ月で５．５ Ｘ ４αの大きさに縮少し、６
ケ月後には完治した。Example 4 70-year-old male. After the cerebral hemorrhage, four heals developed in the sacral region from day one on the 24th, so local disinfection and treatment with soft bath cloths were performed for about a month, but there was no improvement, and in fact, the symptoms tended to spread. Therefore, one tablet obtained in Example 1 was dissolved in 5J warm water, a clean towel was soaked in the solution, and the towel was placed on the t-4i section, a vinyl sheet was placed on top of the towel, and the temperature was increased to 42 Twice a day, the animals were kept warm for 30 minutes by applying a hot water pillow containing hot water. Initially, the size of 9×7 was 4.
Healing decreased to 5.5 x 4α in 2 months, and 6
After several months, he was completely cured.
以上that's all
Claims (1)
のｐＨが４〜７であり、水中で反応してガス泡を発生す
る組成物を水に溶解せしめることにより得られる、二酸
化炭素を３００ｐｐｍ以上含有する溶液からなる褥瘡治
療剤。1. Dioxide, which is obtained by dissolving in water a composition containing a carbonate and an organic acid, whose 0.1% aqueous solution has a pH of 4 to 7, and which reacts in water to generate gas bubbles. A pressure ulcer treatment agent comprising a solution containing 300 ppm or more of carbon.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2247086A JPS62181219A (en) | 1986-02-04 | 1986-02-04 | Remedy for decubitus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2247086A JPS62181219A (en) | 1986-02-04 | 1986-02-04 | Remedy for decubitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62181219A true JPS62181219A (en) | 1987-08-08 |
Family
ID=12083592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2247086A Pending JPS62181219A (en) | 1986-02-04 | 1986-02-04 | Remedy for decubitus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62181219A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999024043A1 (en) * | 1997-11-07 | 1999-05-20 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
| JP2007262083A (en) * | 2007-06-11 | 2007-10-11 | Medion Research Laboratories Inc | Carbon dioxide percutaneous/transmucosal absorption composition |
| JP2011088930A (en) * | 2011-01-18 | 2011-05-06 | Medion Research Laboratories Inc | Carbon dioxide percutaneous and transmucosal absorption composition |
| JP2013163681A (en) * | 2013-04-26 | 2013-08-22 | Medion Research Laboratories Inc | Composition for percutaneous and transmucosal absorption of carbon dioxide |
| JP2013166779A (en) * | 2013-04-26 | 2013-08-29 | Medion Research Laboratories Inc | Composition for carbon dioxide percutaneous-transmucosal absorption |
| JP2013177460A (en) * | 2013-06-18 | 2013-09-09 | Medion Research Laboratories Inc | Composition for percutaneously and transmucosally absorbing carbon dioxide |
| JP2013177461A (en) * | 2013-06-18 | 2013-09-09 | Medion Research Laboratories Inc | Composition for percutaneously and transmucosally absorbing carbon dioxide |
| JP2014088345A (en) * | 2012-10-30 | 2014-05-15 | Toyo Shinyaku Co Ltd | Foamable external preparation for skin |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60112717A (en) * | 1983-11-22 | 1985-06-19 | Kao Corp | Remedy composition for buerger disease |
-
1986
- 1986-02-04 JP JP2247086A patent/JPS62181219A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60112717A (en) * | 1983-11-22 | 1985-06-19 | Kao Corp | Remedy composition for buerger disease |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010275322A (en) * | 1997-11-07 | 2010-12-09 | Medion Research Laboratories Inc | Viscous composition containing carbon dioxide |
| US6689339B1 (en) | 1997-11-07 | 2004-02-10 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
| EP1574207A1 (en) * | 1997-11-07 | 2005-09-14 | Medion Research Laboratories Inc. | Cosmetic use of viscous compositions containing carbon dioxide |
| EP1604645A1 (en) * | 1997-11-07 | 2005-12-14 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
| EP1604646A1 (en) * | 1997-11-07 | 2005-12-14 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
| WO1999024043A1 (en) * | 1997-11-07 | 1999-05-20 | Medion Research Laboratories Inc. | Viscous compositions containing carbon dioxide |
| JP2007262083A (en) * | 2007-06-11 | 2007-10-11 | Medion Research Laboratories Inc | Carbon dioxide percutaneous/transmucosal absorption composition |
| JP2011088930A (en) * | 2011-01-18 | 2011-05-06 | Medion Research Laboratories Inc | Carbon dioxide percutaneous and transmucosal absorption composition |
| JP2014088345A (en) * | 2012-10-30 | 2014-05-15 | Toyo Shinyaku Co Ltd | Foamable external preparation for skin |
| JP2013163681A (en) * | 2013-04-26 | 2013-08-22 | Medion Research Laboratories Inc | Composition for percutaneous and transmucosal absorption of carbon dioxide |
| JP2013166779A (en) * | 2013-04-26 | 2013-08-29 | Medion Research Laboratories Inc | Composition for carbon dioxide percutaneous-transmucosal absorption |
| JP2013177460A (en) * | 2013-06-18 | 2013-09-09 | Medion Research Laboratories Inc | Composition for percutaneously and transmucosally absorbing carbon dioxide |
| JP2013177461A (en) * | 2013-06-18 | 2013-09-09 | Medion Research Laboratories Inc | Composition for percutaneously and transmucosally absorbing carbon dioxide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harpin et al. | Percutaneous alcohol absorption and skin necrosis in a preterm infant. | |
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| JPS62181219A (en) | Remedy for decubitus | |
| Mandel et al. | INTRAVENOUS USE OF PITUITARY ADRENOCORTICOTROPIC HORMONE (ACTH): A REPORT ON ITS ADMINISTRATION IN TWENTY-FIVE PATIENTS | |
| WO2001089537A3 (en) | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders | |
| CN108969795B (en) | One kind is for difficult healedmyocardial surface of a wound functional liquid dressing and preparation method thereof | |
| US6011061A (en) | Therapeutic methods and preparations using rubidium ions | |
| JPH0940563A (en) | Composition for treating bed sore and skin ulcer | |
| CN108938703A (en) | The gynecological gel of quick antibacterial | |
| HUT69724A (en) | Therapeutic method by using caesium ions | |
| CN103585334B (en) | Compound diaper ointment | |
| JP3980843B2 (en) | Foot bath composition | |
| JPH04128219A (en) | Plaster for treating skin ulcer | |
| Nyquist | Brine bath treatments for decubitus ulcers | |
| US3584117A (en) | Medicinal products from placenta tissue and processes of preparing same | |
| KR20100111061A (en) | Composition for wound healing | |
| CN105363007A (en) | Foot bath medicine for treating foot chilblains | |
| AU696938C (en) | Therapeutic methods and preparations using rubidium ions | |
| Smith | Local Treatment with Prontosil Soluble | |
| CN111544490A (en) | Traditional Chinese medicine composition for preventing and treating chilblain | |
| KR101044280B1 (en) | Composition for Burn treatment Using Calcium Oxide | |
| Todd | A practical handbook of Surgical After-Treatment | |
| RU2005480C1 (en) | Medicinal agent | |
| CN103638075A (en) | Sesame oil suspension cream for scalds | |
| Markoe | The use of para-amino salicylic acid in the treatment of tuberculosis |